Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Retained Earnings (2021 - 2026)

Indivior Pharmaceuticals has reported Retained Earnings over the past 6 years, most recently at -$280.0 million for Q1 2026.

  • For Q1 2026, Retained Earnings rose 31.03% year-over-year to -$280.0 million; the TTM value through Mar 2026 reached -$280.0 million, up 31.03%, while the annual FY2025 figure was -$243.0 million, 575.0% down from the prior year.
  • Retained Earnings for Q1 2026 was -$280.0 million at Indivior Pharmaceuticals, down from -$243.0 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $1.4 billion in Q2 2023 and troughed at -$406.0 million in Q1 2025.
  • A 5-year average of $439.8 million and a median of -$33.0 million in 2025 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: soared 200.62% in 2022 and later tumbled 575.0% in 2025.
  • Year by year, Retained Earnings stood at $1.3 billion in 2022, then plummeted by 122.1% to -$288.0 million in 2023, then surged by 87.5% to -$36.0 million in 2024, then tumbled by 575.0% to -$243.0 million in 2025, then fell by 15.23% to -$280.0 million in 2026.
  • Business Quant data shows Retained Earnings for INDV at -$280.0 million in Q1 2026, -$243.0 million in Q4 2025, and -$346.0 million in Q3 2025.